CareDx reports preliminary Q3 revenue of $82-83M, up 23% YoY; testing volume rises 16%

CareDx, Inc.

2024-Q3 EPS reported -$0.49 revenue$247,206,000

Preliminary Q3 2024 revenue $82-83M, up ~23% YoY; testing services $60-61M (+26%).
Testing volume ~44,600 tests, up ~16% YoY; includes $1.2M from prior quarters.
Patient & Digital Solutions rev ~$11.9M (+20%); Products rev ~$10.2M (+7%).
Cash and marketable securities ~$240M, no debt; strong balance sheet.
Full Q3 results to be reported on November 4, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.